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Background: During the last few decades, patients’ rights have been reinforced in many countries by acts of law.
Measures now include health care proxies to uphold the doctor-patient relationship and advance directives for
end-of-life patients. These could be relevant tools as early as the initial diagnosis of haematological malignancies
because of the uncertain disease course. The aim of this research was to assess the factors associated with the
designation of a proxy and writing advance directives by patients in a haematology department in France.
Methods: After a specific programme to encourage discussions about end-of-life preferences, we conducted a
mixed-methods study comprising retrospective analysis of a random sample of 200 patients’ medical records,
crossed with a qualitative analysis of the content of advance directives. Statistical analysis was performed by the
RKward V 0.6.1 software with 0.05 denoting significance. The study was performed and presented in accordance
with the STROBE guidelines. A thematic analysis of the advance directives was performed by two researchers.
Results: A total of 197 medical records were evaluable. The mean age of the patients was 66 years (range: 18–91).
Nearly 2/3 of them (64.5%) designated a proxy, 6.1% wrote advance directives, and 8.1% and 4.6% expressed a wish
to meet a religious representative or a volunteer, respectively. The 2-year survival rate was 78.4% [95%CI: 68.2-90.2].
Patients who wrote advance directives were statistically older (p <0.00025). Patients who wrote an advance directive
were more likely to have expressed a wish to meet a religious representative (p <0.001) or a volunteer (p = 0.003).
Marital status was a significant factor in appointing a proxy (p = 0.04).
Conclusions: To the best of our knowledge, this is the first paper to identify influencing factors for proxies and
advance directives in a homogenous population of patients with haematological malignancies. Most patients chose
a proxy. However, despite several training programmes for the carers and a care planning programme, few patients
wrote advance directives. Our findings suggest that influencing factors are advanced age and a wish to see a
religious representative. This study highlights the importance of oral communication about end-of-life issues
between carers, patients and their relatives.
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Over the last few decades, patients’ rights have been
enforced in many parts of the world by acts of law [1-4].
Nevertheless, their implementation within hospital units
varies [5-7] according to the pathology and culture, par-
ticularly when comparing North America and Europe
[8-10], and various publications [11-13] report insufficient
uptake both by carers and the general public. Previous
studies have focused more on the carers’ theoretical per-
ception of the law [14,15] rather than the patients’ percep-
tion [16]. In France, the “Patients’ Rights and End-of-Life
Care” Act dated April 22, 2005 [4], emphasizes the role of
the health care proxy (HCP) and advance directives
(ADs). However, in 2011, the French National Observatory
of the End of Life, described them as “misunderstood,
difficult to use tools” [13].
To the best of our knowledge, no such studies have been
conducted in the context of haematological malignancies
(HM). These diseases have a particularly poor prognosis
and the risk of dying remains in the foreground through-
out the clinical pathway. Moreover, sceptic shock or
sudden bleeding can occur during induction therapy or in
advanced stage disease. It is thus logical to introduce the
concepts of HCP and AD to a patient in this setting.
The main goal of this study was to assess the factors
associated with the designation of an HCP and writing
ADs by patients presenting with an HM both quantita-
tively (how many patients) and qualitatively (content of
ADs). The secondary objective was to assess the link
between these tools and the patient’s wish to meet a
volunteer or a religious representative.
Methods
Additional file 1: Table S1 summarizes the multi-step
procedure initiated in 2008 in our centre to implement
the 2005 “Patient’s Rights and End-of-Life Care” Act. Our
programme aims to inform patients and carers about
HCPs, ADs and to encourage discussions about end-of-
life preferences. Carers were trained to present the con-
cept of an HCP and AD to the patient and we revised the
patient welcoming procedure. All the patients are asked to
complete the “patient information form” on arrival. They
have the choice to designate an HCP, write an AD and
express a wish to meet a volunteer or a religious represen-
tative. The AD that we use comprises very few instruc-
tions so as not to influence the patient’s choices and
encourage the patient to express him/herself freely. We
used a mixed-methods approach to collect the data and
combine quantitative and qualitative methods to integrate
the various relevant perspectives to study HCP and ADs.
Sample selection
Two hundred medical records of patients presenting
with an HM and treated in the Haematological Unit of aUniversity Hospital (Limoges, France) from June 1, 2008 to
April 30, 2012 were randomly drawn. Data was extracted by
a clinical research engineer using an abstraction protocol to
perform a retrospective descriptive quantitative analysis [17].
Demographic and study data were collected from the patient
information form which is completed by all patients on their
first visit to the centre and kept in their medical records.
Any medical records without this patient information
form filled in by the patient or his legal representative were
not retained for analysis. Study data included: whether an
HCP had been designated, whether an AD had been writ-
ten and was available, mention of a wish to meet a reli-
gious representative or a volunteer. The survival data of
the patients was updated on July 5, 2013.
Statistical analysis
The statistical studies were performed by using the soft-
ware RKward V 0.6.1 with a significance level of 0.05.
Analysis was performed in accordance with the STROBE
guidelines. The quantitative variables were studied for
their average compared to the standard deviation, or me-
dian, and for their interquartile range. The qualitative vari-
ables were studied by headcount and percentage.
Binomial univariate logistic regression: the significantly
associated variables presenting a predictive factor for HCP
or ADs were identified using a multivariate logistic regres-
sion model with two dependent variables (HCP or ADs)
and independent variables (age, diagnosis, gender, date of
the patient information form, marital status, pathology, re-
ligious representative and volunteer visit). Relevant vari-
ables and those presenting a level of significance below
0.20 in univariate analysis were introduced in the multi-
variate model. A stepdown procedure was performed with
a level of significance below 0.05. For statistical analysis,
the variables mentioned above were categorized as fol-
lows: age group on diagnosis (under 69 or over 70 years);
gender (M/F); date (year) of the patient information form
(2008–2009, 2010, 2011–2012); marital status (married or
with a partner, single, unspecified); pathology (myeloid
pathologies and others, lymphoid pathologies); a wish to
meet a religious representative (yes, no, n/a); wish to meet
a volunteer (yes, no, n/a).
Qualitative analysis
Data collection
Qualitative data was collected from written ADs available
in the patient information form.
Data analysis
The aim of the qualitative analysis was not to be ex-
haustive but rather to provide an overall understanding.
All the data were listed on a spreadsheet. No specific
qualitative data analysis software was used. The data
were analysed according to qualitative content analysis
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ically, we performed a thematic analysis of the content
of the ADs after identifying the main messages and key-
words and assessing recurrence.
The analytical process was conducted by a multidisciplin-
ary research team consisting of a senior haematologist and
a clinical research engineer trained in qualitative research,
medical law and clinical ethics. Initially, both researchers
read the six ADs independently to familiarize themselves
with the data. Then they independently analysed each AD
and coded data according to the rules. Codes were subse-
quently compared, contrasted, and grounded in data before
being abstracted to related categories. During the analysis
there was an ongoing discussion of emerging themes and
keywords, and variance of interpretation in the study was
resolved through communicative validation.
Terminology
For this study, HCP was defined in accordance with
French regulations [4] as a person chosen by the patient
for two types of missions: first, to support him/her in
making decisions throughout the healthcare pathway
and second, to speak on his/her behalf for future health-
care decisions in case the patient is unable to express
wishes him/herself. The HCP can never make a decision
in place of the patient.
ADs are a written document by which the patient ex-
presses his/her preferences in case he/she is unable to
express them. The patient indicates his/her wishes re-
garding the end of life and the conditions for limiting
or stopping treatment.
Both an HCP and AD are strictly informative and the
final decision belongs to the physician.
Ethics
The Ethics Committee of the University Hospital of Limoges
approved the study. According to French health regulations
no written informed consent is required as the research is a
retrospective observational study on registered data. Oral
consent was obtained prior to the research by all participants.
Results
Demographic data
A total of 2180 medical records were listed during the
study period. Among them, 200 were randomly selected
and 197 (98.5%) patient information forms retained for
analysis. Three (1.5%) were excluded for missing data. The
patients characteristics are summarized in Table 1. There
were no significant differences in the number of patients
designating an HCP or writing an AD throughout the
period (2008–2009, 2010, 2011–2012) from when the infor-
mation programme was introduced to the end of the study.
The sex ratio was 1.26, the average age was 64.4 ± 15.8
[range: 18–91] years and 73 (37.0%) were 70 years orolder. A total of 136 (69.0%) and 61 (31.0%) patients pre-
sented with malignant lymphoid and malignant myeloid
pathologies and others, respectively. The 2-year survival
rate of the entire cohort was 78.4% [95% CI: 68.2-90.2].
Sixteen patients (8.1%) expressed a wish to meet a reli-
gious representative and nine (4.6%) a volunteer.
Description of the sample of patients who designated a
health care proxy
Quantitative content analysis
Among the 197 evaluable medical records, 127 patients
had designated a HCP (64.5%). The characteristics of these
patients are summarized in Table 2. The sex ratio was 1.27
and the average age 64.8 ± 14.2 [range: 23–91] years.
Among them, only 12 patients (75.0%) expressed a wish to
meet a religious representative and six (66.7%) a volunteer.
A total of 118 (93.0%) patients chose a relative as their
HCP: either the spouse for 76 patients (60.0%) or a des-
cendant for 30 (24.0%). Patients living with a partner,
either married or not, preferentially chose their partner
(n = 66, 77.5%). The HCP was somebody from outside of
the family for four patients (2.6%) and only three (2.0%)
chose their physician. Among the seven patients who
designated several HCPs, five were married or with a
partner (four of them designated their wife or husband
as first choice and chose simultaneously their children
or stepchildren, and one chose simultaneously two chil-
dren and one stepdaughter). The two remaining single pa-
tients designated three children or two relatives respectively.
The only factor that emerged in univariate analysis as
associated with the designation of an HCP was marital
status: OR 2.4 [95% CI: 1.0-5.9], p = 0.040. (Table 3).
Table 4 summarizes the results of the multivariate
analysis. Marital status remained a significant factor:
OR 2.4 [95% CI: 1.0-5.9], p = 0.040.
Description of the sample of patients who wrote advance
directives
Quantitative content analysis
ADs were sampled in the medical records of 12 (6.1%) pa-
tients (Table 1). Patients who wrote ADs were equally men
or women, with an average age of 72.5 ± 5.6 [range: 62–83]
years at the time of diagnosis. Seven (9.6%) were 70 or older
and overall this group was statistically older than the rest of
the cohort (p = 0.00025). Six of them (37.5%) expressed a
wish to meet a religious representative and three (33.3%) a
volunteer.
Gender, age and marital status had no predictive
value for the writing of ADs, but there were more pa-
tients with lymphoid pathologies than with myeloid
pathologies (p = 0.027) OR 4.1 [95% CI: 1.2-16.3]. The
most significant factors for writing an AD were the
wish to meet a religious representative (p < 0.001) or a
volunteer (p = 0.003) (Table 5).
Table 1 Characteristics of the cohort of patients
Total sample Health care proxy Advance directives
Yes No N/A Yes No N/A
n. % n. % n. % n. % n. % n. % n. %
Year medical records were studied
2008-2009 60 30.5 35 58.3 14 23.3 11 18.3 3 5.0 34 56.7 23 38.3
2010 54 27.4 38 70.4 10 18.5 6 11.1 4 7.4 34 63.0 16 29.6
2011-2012 83 42.1 54 65.1 14 16.9 15 18.1 5 6.0 52 62.7 26 31.3
Population 197 100.0 127 64.5 38 19.3 32 16.2 12 6.1 120 60.9 65 33.0
Gender
Male 110 55.8 71 64.5 21 19.1 18 16.4 6 5.5 72 65.5 32 29.1
Female 87 44.2 56 64.4 17 19.5 14 16.1 6 6.9 48 55.2 33 37.9
Sex ratio 1.26 1.27 1
Age groups on diagnosis
<70 124 63.0 79 63.7 27 21.8 18 14.5 5 4.0 83 66.9 36 29.0
≥70 73 37.0 48 65.8 11 15.1 14 19.2 7 9.6 37 50.7 29 39.7
Median age (years) 66 67 73
Average age (years) SD (min-max) 64.4 ± 15.8 [18;91] 64.8 ± 14.2 [23;91] 72.5 ± 5.6 [62;83]
Marital status
Married or with a partner 138 70.1 98 71.0 24 17.4 16 11.6 9 6.5 87 63.0 42 30.4
Single/Widowed 44 22.3 19 43.2 11 25.0 14 31.8 3 6.8 22 50.0 19 43.2
Not filled in 15 7.6 10 66.7 3 20.0 2 13.3 - - 11 73.3 4 26.7
Pathologies
Lymphoid pathologies1 136 69.0 91 66.9 26 19.1 19 14.0 4 2.9 81 59.6 51 37.5
Myeloid pathologies and others2 61 31.0 36 59.0 12 19.7 13 21.3 8 13.1 39 63.9 14 23.0
Wish to meet a religious representative
16 8.1 12 75.0 1 6.3 3 18.8 6 37.5 9 56.3 1 6.3
Wish to meet a volunteer
9 4.6 6 66.7 1 11.1 2 22.2 3 33.3 5 55.6 1 11.1
1Lymphoid pathologies: NHL, Hodgkin’s disease, Hairy cell leukaemia, myeloma, amyloidosis, Waldenstrom’s disease, CLL).
2Myeloid pathologies and others: acute leukaemia and myelodysplasia (RAEB), CMML, myeloproliferative disorders (CML, primary myelofibrosis, essential
thrombocythemia, polycythemia vera, rare non malignant haemopathies (aplastic anemia, severe autoimmune cytopenias, thrombotic microangiopathies,
immune deficiencies.
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patient to meet a volunteer was significant (p = 0.003):
OR 13.0 [95% CI: 2.2-72.1] (Table 4).
Only six ADs (50.0%) were filed. One person confirmed
his ADs three years after writing it, which is the maximum
period of legal validity. Life expectancy was significantly
shorter for patients who wrote an AD than those who did
not or who did not express an opinion. The average lapse
of time between the filling in the patient information form
and the patient’s death was 1.41 years.
Qualitative findings
Content analysis of the six filed ADs by two researchers
revealed two main themes: the first comprised wishes
regarding medical care, in particular life-sustaining
treatment, and was addressed to the haematologist orthe family doctor (Participants 2, 3 and 5); the second
theme referred to more personal messages the patients
wished to express to their relatives regarding their
personal philosophy about end of life (Participants 1, 2,
3 and 4). Six key terms emerged from this analysis:
“life-sustaining treatment”, “my children,” “mental faculties”,
“survival”, “suffering” and “pain”.
Them 1: patients’ wishes about medical care decisions
Two patients began their directives by asserting that they
wereof soundmindandemphasizinghow important their
stateofconsciousnesswas for them:
In full possession of my mental and physical faculties,
such are my directives… I intend to be as conscious as
possible at the time of my death… (Participant 2)
Table 4 Multivariate analysis
Result of analysis by multivariate binomial logistic regression using a
step-down method of factors associated with the designation of a
health care proxy
Variables Odds Ratio 95% CI p-value
Marital status
Single 1.0
Married or with a partner 2.4 [1.0-5.9] 0.040
Result of analysis by multivariate binomial logistic regression
using a step-down method of factors associated with the writing
of advance directives
Variables Odds Ratio 95% CI p-value
Wish to meet a volunteer
No 1.0
Yes 13.0 [2.2-72.1] 0.003
Table 2 Designation and identity of the health care proxy
Designation of a health care proxy n. %
Yes 127 64.5
No 38 19.3
Not filled in 32 16.2
Total n = 197 100%
Identity of the chosen person
Spouse/Partner 76 60
Child 30 24
Close relative (cousin, nephew, in-law) 5 4




Total n = 127 100%
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regression of the factors associated with the designation
of a health care proxy
Variables Odds Ratio 95% CI p-value
Gender
Male 1.0
Female 0.9 [0.4-2.0] 0.944
Age
<70 years 1.0
≥70 years 1.4 [0.6-3.3] 0.320
Marital status
Single 1.0
Married or with a partner 2.4 [1.0-5.9] 0.040
Pathology
Myeloid and others 1.0





Wish to meet a religious representative
No 1.0
Yes 4.0 [0.7-76.1] 0.185
Wish to meet a volunteer
No 1.0
Yes 2.0 [0.3-39.0] 0.522I, the undersigned Mr B…, being of sound mind if not
of sound body, hereby declare… (Participant 5)
The patients anticipated the possibility that they might
lose their faculty of expression:
A worsening of my state of health… (Participant 1)
A deterioration of my faculties… (Participant 2)
If the progression of my state suddenly reduces my free
will, whatever the cause, I request… (Participant 5)
All the patients expressed their refusal of life-sustaining
care, but only some of them explained what they meant
by that term:
I wish to be spared from all aggressive therapy, as well
as all artificial means of survival that would leave me
deprived of my mental faculties or suffering from
intolerable pain. (Participant 3)
I do not want any life-sustaining care… (Participant 1)
I refuse all life-sustaining care… (Participant 4)
No life-sustaining care, I do not want to be a guinea
pig… (Participant 6)
Some ADs were unequivocal, others were more diffi-
cult to interpret. Sometimes a discrepancy appeared
between the refusal of life-sustaining treatments and the
fact that the patient still agreed to receive some of them:
I request that my life is not prolonged… I have
survived thanks to transfusions for four years… Let the
Table 5 Analysis by univariate binomial logistic regression of the factors associated with the writing of advance
directives
Variables Odds ratio 95%CI p-value
Gender
Male 1.0
Female 1.5 [0.4-5.0] 0.504
Age
<70 1.0
≥70 3.1 [0.9-11.2] 0.064
Marital status
Single 1.0
Married or with a partner 1.1 [0.2-7.8] 0.874
Pathology
Myeloid and others 1.0
Lymphoid 4.1 [1.2-16.3] 0.027
Time period
2008 -2009 1.0 0.947
2010 1.3 [0.2-7.2]
2011-2012 1.0 [0.2-5.5]
Wish to meet a religious representative
No 1.0
Yes 14.2 [3.6-59.2] <0.001
Wish to meet a volunteer
No 1.0
Yes 13.0 [2.2-72.1] 0.003
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free them of all civil and penal responsibility…
(Participant 5)
The patients indicated what they agreed to and refused
in terms of medical techniques. They mentioned pallia-
tive care and pain relief:
Yes for administration of painkillers, so that the pain
will not prevent me from serenely expressing myself…
(Participant 2)
I wish to be spared from intolerable suffering…
(Participant 3)
I fear all pain… (Participant 5)
Two concepts of medicine emerged: palliative treatment
providing support for the patient on one hand and tech-
nical intervention on the other. This led patients to refuse
some treatments perceived as futile or associated with a
fear of medicine:Yes to palliative care. No to all aggressive care.
No to any surgery that would leave the final
prognosis unchanged… (Participant 2)
Should the possibility arise, I absolutely refuse
all resuscitation (Participant 4)
Sometimes, the patient refused treatments which could
lead to disability due to secondary effects:No to all drugs likely to induce the loss of my
remaining faculties (sight, mobility, bodily functions)…
(Participant 2)The more explicit AD made references to the patient’s
medical history, to his quality of life, perceived as less
than satisfying, to the disorders or symptoms he suffered
from, to his fears and anxiety:My main anxiety is choking and suffocation. My own
father died in my home by suffocation… unable to
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I had that day was too acute for time to erase…
(Participant 5)
The serious structural weakness, which is worsening as
my disease progresses, is taking me from my armchair
to my bed to drowse or to sleep… (Participant 5)
ADs were also a means for the patient to bring up the
question of the place of death, or to allude to complex
family relationships:
Following the patient information form I just
completed, I inform you that in case of hospitalization
and worsening of my state, I do not wish to die in L…
I express a very doubtful opinion regarding the
information my daughter will be supplied with…
(Participant 1)
Theme 2: personal messages to relatives or a personal
philosophy about end of life
ADs were also used to communicate their thoughts on
the meaning of life, personal quest for serenity, and to
show how much they trusted their loved ones:I have had my time… Life is a marvel but one must
know how to end even the best of things. I will have
lived enough… (Participant 5)
My sincere desire is to end the path of my life with the
best support, so that it will reach its conclusion in all
serenity… (Participant 4)
In case of deterioration of my faculties, I trust my
wife and any of my six children to make a decision
according to the spirit of the present document…
(Participant 2)Two patients referred to the use of this document and
the implications it could have in making future medical
decisions:I thank you in advance for the attention you
will give to me… (Participant 4)
I thank you for agreeing to take these guidelines
into consideration… (Participant 1)Discussion
The main findings of this mixed-method approach to
better understand which factors influence patients with
an HM in using end-of-life tools are that: i. patients with
partners are more likely to appoint an HCP and, ii. patients
wishing to meet a religious representative or a volunteer
are more likely to write an AD. This significant difference
in ADs in terms of religious belief has never been de-
scribed before except for euthanasia requests [8]. Further-
more, this is the first paper to provide a qualitative analysis
of the AD content in [19-22] a population of patients with
HM. Two main themes emerge: wishes relative to medical
treatment on one hand, and personal messages to loved
ones on the other.
The patients who designated an HCP in our study
were older than those from previously published works
presenting with other pathologies [23-25]. The propor-
tion of patients who were married or with a partner in
our study was similar to that of patients admitted for
surgical procedures (71.0% vs.76.0%, respectively) [26].
However, this figure is much higher than that found in
the general French population (47.0%) [27].
None of the factors of gender, age, pathology or expres-
sion of a wish to meet a volunteer or a religious represen-
tative were found to be a significant influence on whether
a patient chooses to designate an HCP. This is in contrast
to the findings of Halpern et al. [24] who showed that age
is a significant factor and that there is a relationship be-
tween the designation of an HCP and religion and spiritu-
ality. However, it is difficult to compare the studies
directly. Demographical data are rarely if ever published at
a national level. Furthermore, the concept of ADs in the
US [2] is different as the term is used indiscriminately for
both ADs and HCPs.
Overall, patient/carer relationships have been changing
recently in France towards a model that encourages more
patient autonomy. Talking about a subject as sensitive and
difficult as end of life is possibly easier with an HCP.
In our study, we found a higher rate of HCP designation
(64.5%) than the national rate in France (5.0%) [5] though a
similar rate to that found in the US [24]. The main factors
for designating an HCP are related to culture and the coun-
try, the pathology and also how advanced the society is in
dealing with this kind of procedure: percentages vary enor-
mously from nearly 30% in Europe to 0.0% in Japan [28].
Among the reasons potentially explaining HCP designa-
tion is the diagnosis of a severe disease, as in our setting,
where patients have more of an acute need. Furthermore,
the high rate we observed in our population could also be
a reflection of our active information programme includ-
ing patient information documents and workgroups com-
prising doctors, caregivers, and a jurist specialized in
medical law which might have facilitated exchanges on the
subject. However, in spite of this multi-step programme
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increase in the number of patients designating HCPs or
writing ADs over the study period.
The most frequently designated HCP were members
of the patient’s family (93.0%), which matches other re-
ports found in the literature [16,19,26,28,29]. French law
stipulates that a patient can only designate a single HCP;
however, seven of our patients designated several HCPs.
This might indicate a difficulty in choosing between
children and spouse [19].
The people who wrote ADs tended to be older – 75.5 years
as opposed to 65.4 – similarly to other studies finding that
older patients are more likely to write ADs [19,20,24].
People who wrote an AD were also more likely to express
a wish to meet a religious representative and a volunteer
simultaneously regardless of practice or belief, or religion
(although Catholicism was the only religion mentioned by
the patients who expressed a wish to meet a religious repre-
sentative (56.3%)). The need for spirituality and religious
support is described in the literature as playing an import-
ant role in palliative care [10,30-33].
The fact that the ADs were written after diagnosis
could suggest that the wishes expressed are more the
consequence of the patient’s personal experience rather
than a reaction when faced with imminent death.
The desire to meet a volunteer could attest to a need
to open up to others. When someone is diagnosed with
a severe disease they are forced to face up to the reality
of their own mortality and this leads to introspection or
contemplation about their relationships with other
people and the world in general. This questioning can
result in a need for spirituality.
The low number of ADs written by our patients with
an HM (6.0%) was similar to that found in a French
study carried out in various medical units (6.0%) [15],
but is higher than the results of a national French obser-
vatory study (2.5%) [33]. These results are close to those
observed in Europe (from 2.0% to 18%) and reflect the
limited use of ADs despite encouragement through spe-
cific legislation [19,34]. The low figures can be explained
by the fact that patients are either not aware of this con-
cept (90.0%) or have a negative perception of it
[15,31,32]. Conversely, more patients write ADs in the
US (from 1.5% to 71.0%) depending on the population
studied, and this highlights major cultural differences
between Europe and the US [30,35-39].
Among the registered ADs, two were not archived and
the haematologist did not ask the patients to transmit
them based on the argument of the anxiety it could trig-
ger. ADs are often assimilated to death, making it diffi-
cult for the carers to approach the subject. On the data
updated on July 5, 2013, most of the patients who wrote
an AD had died (n = 4/6) although the mortality for the
whole studied cohort was 27.4%.All ADs were written on blank paper and not on a
pre-printed form and comprised one to two pages.
When a patient went into more detail about what they
accepted or refused in terms of medical care, they referred
to their own experience and gave limits for a specific treat-
ment or determined a degree of handicap that was not ac-
ceptable to them [40]. Past family experience of the
disease was also referred to with a very accurate descrip-
tion of the symptoms the patient witnessed personally and
expressing a desire not to suffer the same fate.
Furthermore, no ADs expressed a wish to have every-
thing done to sustain life regardless of prognosis or
cost. Few patients used ADs as a way to ponder on the
meaning of life, the end, or to declare his/her spiritual
quest.
The people who wrote ADs were able to pursue a
personal reflection about their disease, to anticipate
their incapacity to express their will and to envisage
their own death. They simultaneously designated an
HCP (75.0%) suggesting a need to exchange orally as
well as in writing. This finding matches other reports in
the literature [39,41].
The finding that so few ADs are written in this patient
population would seem to suggest that this tool only re-
sponds to the needs and expectations of a minority of
patients. This raises questions about the whole of con-
cept ADs and how best to encourage patients to com-
municate their wishes concerning treatment and how
they would like to be supported.
At a time of particular fragility, HCPs and ADs make
tangible a confrontation with the idea of our own end. This
is particularly important in the society in which we live as
the rituals that previously helped us tame our fear of death
gradually fade away. This psychological aspect should not
be neglected. The Terror Management theory argues that
human understanding of mortality creates an existential
anxiety that must be kept under constant control. Defences
are erected to keep thoughts about death as far removed
from the consciousness as possible [42,43]. Not everybody
can face their own death and write about it.
Moreover, the implementation of HCPs and ADs could
undermine a type of carer/patient communication which is
both oral and based on trust. Informal oral ADs do not
exist in the US but represent 11.0% of German ADs [28]
while they have not been analysed in France. Trust in rela-
tives and in the medical team is sufficient for some patients
who do not see the need to formalize words discussed in
private. One publication shows only one patient out of
three goes the whole way in the process of writing [44]. It
would thus appear essential to respect the will and rhythm
of the patient to communicate in his/her own way on such
a sensitive subject as the end of life. ADs and HCP should
not replace a discussion with the patient who might prefer
to express his/her wishes in this way.
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Apart from concerns of potential selection bias and con-
founding factors inherent to any retrospective study,
some other limitations deserve to be mentioned. First, it
took place in a single centre and thus cannot be general-
ized to all patients presenting with an HM. Furthermore,
similar to other mixed-method studies the qualitative
and quantitative approaches took place in a sequential
order thus limiting the integration of both data forms
under a unified process of data analysis. However, the
mixed-method approach is highly relevant when dealing
with current public health issues, It allows researchers to
combine the strengths of qualitative and quantitative
methodologies and can reveal which variables are re-
lated, the predictive nature of one variable over another
and the characteristics of this predictive relation. An-
other limitation of the study is the low number of ADs
available. Moreover, we did not explore what motivates
the patient to choose an HCP and whether HCPs
provide a true opportunity for dialogue [45] or rather
constitute a mere administrative formality. Gathering
the opinions of carers to assess their perception of HCPs
and ADs could also have been of interest. These points
could be the focus of complementary studies.Conclusions
The findings of our study highlight that, despite an
advance care planning programme to assist patients and
the training of caregivers, few people choose to write
ADs. Accompanying a patient through the process of
designating an HCP and writing ADs requires time and
allocation of support personnel. Both tools are a poten-
tial opportunity for starting up a much needed dialogue
with a patient facing a life-threatening disease. The fact
that only a few patients presenting with severe HM write
ADs, would indicate that the need remains to be better
defined by French patients. Furthermore, as some patients
could find the formal approach of writing difficult, infor-
mal oral communication about wishes with carers and
relatives should also be encouraged as it represents an op-
portunity to develop a good doctor/patient relationship.Additional file
Additional file 1: Table S1. Multi-step procedure initiated in our
clinical haematology department to implement the 2005 Patient’s Rights
and End-of-Life Care Act.Abbreviations
HCP: Healthcare proxy; AD: Advance directives; HM: Haematological
malignancies.
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